Oxxon Pharmaccines relocates
Oxford-based Oxxon Pharmaccines, a mid-stage biotechnology company developing innovative immunotherapeutics, has moved to a new, larger site on the prestigious Oxford Science Park.
Oxford-based Oxxon Pharmaccines, a mid-stage biotechnology company developing innovative immunotherapeutics, has moved to a new, larger site on the prestigious Oxford Science Park.
With the progression of Oxxon's immunotherapeutics into Phase II clinical trials, combined with the development of in-house clinical and immunoassay competencies, Oxxon has outgrown the Oxford BioBusiness Centre that had housed the Company since its inception.
The new 700m2 premises represent a five-fold increase in the company's laboratory and commercial space and will allow new staff to be taken on. Some 60% will consist of laboratory space with the remaining 40% comprising offices and general facilities.
'This expansion is driven by the continued clinical development of Oxxon's immunotherapeutic programmes and will enable Oxxon to reap the benefit from business opportunities arising from the exploitation of its PrimeBoost technology,' said Dr Deirdre Gillespie, Oxxon's ceo. Following the completion of our £15m funding round we are now expanding our commercial resources and clinical capabilities in Oxford.'
Oxxon's proprietary Heterologous PrimeBoost approach consists of a novel two-stage method for stimulating a specific and effective immune response against infectious diseases and cancer. Efficacy in animals and preliminary efficacy data in man have been demonstrated. Although PrimeBoost is broadly applicable, Oxxon will focus its resources on the development of immunotherapeutics for chronic infectious disease and cancer in man, and it has already progressed its PrimeBoost products for the treatment of hepatitis B and malignant melanoma into Phase II clinical trials. The Company also has number of preclinical products in development.